S
Shanghai Junshi Biosciences Co Ltd
SSE:688180
Shanghai Junshi Biosciences Co Ltd
SSE:688180
Price:
29.71 CNY
-1.85%
Market Closed
Updated:
May 21, 2024
Balance Sheet
Balance Sheet Decomposition
Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co Ltd
| Current Assets | 5.6B |
| Cash & Short-Term Investments | 3.8B |
| Receivables | 999.6m |
| Other Current Assets | 792.8m |
| Non-Current Assets | 5.8B |
| Long-Term Investments | 1.1B |
| PP&E | 3.9B |
| Intangibles | 547m |
| Other Non-Current Assets | 196m |
| Current Liabilities | 2.4B |
| Accounts Payable | 1.4B |
| Accrued Liabilities | 280.6m |
| Short-Term Debt | 457.1m |
| Other Current Liabilities | 319.6m |
| Non-Current Liabilities | 1.8B |
| Long-Term Debt | 1.2B |
| Other Non-Current Liabilities | 540m |
Balance Sheet
Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co Ltd
Currency: CNY
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
266
|
2 764
|
1 214
|
3 385
|
3 505
|
6 000
|
3 779
|
|
| Cash |
0
|
0
|
0
|
0
|
3 505
|
5 997
|
3 778
|
|
| Cash Equivalents |
266
|
2 764
|
1 214
|
3 385
|
0
|
3
|
1
|
|
| Short-Term Investments |
152
|
6
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
10
|
44
|
198
|
698
|
1 456
|
347
|
1 000
|
|
| Accounts Receivables |
1
|
7
|
163
|
590
|
1 293
|
238
|
483
|
|
| Other Receivables |
9
|
37
|
35
|
108
|
163
|
109
|
516
|
|
| Inventory |
31
|
49
|
181
|
343
|
485
|
599
|
538
|
|
| Other Current Assets |
57
|
49
|
318
|
272
|
399
|
271
|
255
|
|
| Total Current Assets |
515
|
2 910
|
1 911
|
4 699
|
5 845
|
7 216
|
5 571
|
|
| PP&E Net |
551
|
1 129
|
1 926
|
2 507
|
3 153
|
3 297
|
3 896
|
|
| PP&E Gross |
551
|
1 129
|
1 926
|
2 507
|
3 153
|
3 297
|
3 896
|
|
| Accumulated Depreciation |
34
|
62
|
115
|
258
|
472
|
729
|
1 001
|
|
| Intangible Assets |
70
|
76
|
143
|
162
|
265
|
316
|
547
|
|
| Goodwill |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
69
|
56
|
126
|
154
|
154
|
42
|
58
|
|
| Long-Term Investments |
1
|
19
|
142
|
423
|
1 485
|
1 403
|
1 133
|
|
| Other Long-Term Assets |
13
|
60
|
165
|
52
|
133
|
284
|
138
|
|
| Other Assets |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
1 220
N/A
|
4 250
+248%
|
4 412
+4%
|
7 997
+81%
|
11 035
+38%
|
12 558
+14%
|
11 343
-10%
|
|
| Liabilities | ||||||||
| Accounts Payable |
21
|
217
|
327
|
798
|
1 585
|
1 057
|
1 381
|
|
| Accrued Liabilities |
16
|
53
|
120
|
212
|
223
|
233
|
281
|
|
| Short-Term Debt |
0
|
178
|
77
|
21
|
0
|
351
|
457
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
14
|
256
|
45
|
84
|
123
|
|
| Other Current Liabilities |
21
|
23
|
41
|
185
|
148
|
40
|
197
|
|
| Total Current Liabilities |
59
|
471
|
578
|
1 473
|
2 001
|
1 766
|
2 438
|
|
| Long-Term Debt |
0
|
392
|
772
|
573
|
583
|
886
|
1 213
|
|
| Minority Interest |
1
|
1
|
0
|
0
|
371
|
293
|
169
|
|
| Other Liabilities |
42
|
73
|
84
|
124
|
134
|
130
|
371
|
|
| Total Liabilities |
99
N/A
|
935
+843%
|
1 434
+53%
|
2 170
+51%
|
3 090
+42%
|
3 075
0%
|
4 192
+36%
|
|
| Equity | ||||||||
| Common Stock |
585
|
760
|
784
|
873
|
911
|
983
|
986
|
|
| Retained Earnings |
519
|
1 242
|
1 999
|
3 668
|
4 389
|
6 777
|
9 060
|
|
| Additional Paid In Capital |
1 056
|
3 797
|
4 180
|
8 632
|
11 423
|
15 346
|
15 395
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
19
|
97
|
181
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
27
|
|
| Other Equity |
1
|
0
|
13
|
9
|
19
|
28
|
38
|
|
| Total Equity |
1 121
N/A
|
3 315
+196%
|
2 978
-10%
|
5 828
+96%
|
7 945
+36%
|
9 484
+19%
|
7 151
-25%
|
|
| Total Liabilities & Equity |
1 220
N/A
|
4 250
+248%
|
4 412
+4%
|
7 997
+81%
|
11 035
+38%
|
12 558
+14%
|
11 343
-10%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
585
|
760
|
784
|
873
|
911
|
983
|
985
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
